Bergeron Anne
Respiratory Medicine Department, AP-HP, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, Paris F-75010, France; Sorbonne Paris Cité, UMR 1153 CRESS, Biostatistics and Clinical Epidemiology Research Team, Univ Paris Diderot, 1 Avenue Claude Vellefaux, Paris F-75010, France.
Clin Chest Med. 2017 Jun;38(2):249-262. doi: 10.1016/j.ccm.2016.12.013. Epub 2017 Mar 3.
Late-onset noninfectious pulmonary complications (LONIPCs), most of which occur between 3 months and 2 years following allogeneic hematopoietic stem cell transplantation (HSCT), have a significant effect on patient outcomes and are highly associated with mortalities and morbidities. LONIPCs can involve all anatomic lung regions: bronchi, parenchyma, vessels, and pleura; this diversity can lead to various clinical entities. Bronchiolitis obliterans syndrome is the most frequent LONIPC. Most LONIPCs are associated with graft-versus-host disease. Evaluation of prophylactic strategies for LONIPCs is necessary to improve outcomes in high-risk allogeneic HSCT recipients.
迟发性非感染性肺部并发症(LONIPC)大多发生在异基因造血干细胞移植(HSCT)后的3个月至2年之间,对患者的预后有重大影响,且与死亡率和发病率高度相关。LONIPC可累及肺部所有解剖区域:支气管、实质、血管和胸膜;这种多样性可导致各种临床病症。闭塞性细支气管炎综合征是最常见的LONIPC。大多数LONIPC与移植物抗宿主病相关。评估LONIPC的预防策略对于改善高危异基因HSCT受者的预后很有必要。